Showing results (1-10 of 41) with videos related to
Sort By:
Pageof 5
Frontiers in Public Health|August 5, 2025
Cost-effectiveness analysis of cadonilimab plus chemotherapy as a first-line treatment option in HER-2-negative advanced gastric cancerLongfeng Zhang, Qingsheng Yang, Zhiwei ZhengFrontiers in Immunology|July 16, 2025
Toripalimab plus chemotherapy versus chemotherapy as first-line therapy for extensive-stage small cell lung cancer: a cost-effectiveness analysisLongfeng Zhang, Hongcai Chen, Huide Zhu, et al.Journal of Comparative Effectiveness Research|May 19, 2020
Lenvatinib versus sorafenib for unresectable hepatocellular carcinoma: a cost-effectiveness analysisHongfu Cai, Longfeng Zhang, Na Li, et al.Journal of Comparative Effectiveness Research|February 18, 2022
Cost-effectiveness of pembrolizumab for second-line treatment of esophageal squamous cell carcinoma patients with a combined positive score of 10 or moreXiaobing Song, Zhiwei Zheng, Xiuli Li, et al.Frontiers in Oncology|December 21, 2020
First-Line Durvalumab Plus Platinum-Etoposide Versus Platinum-Etoposide for Extensive-Stage Small-Cell Lung Cancer: A Cost-Effectiveness AnalysisLongfeng Zhang, Yongfu Hang, Maobai Liu, et al.Leukemia & Lymphoma|June 5, 2019
Cost-effectiveness analysis on binary/triple therapy on the basis of ixazomib or bortezomib for refractory or relapsed multiple myelomaHongfu Cai, Longfeng Zhang, Na Li, et al.Annals of Palliative Medicine|December 11, 2020
Multiple combination therapy based on intrathecal pemetrexed in non-small cell lung cancer patients with refractory leptomeningeal metastasisQian Miao, Xiaobin Zheng, Longfeng Zhang, et al.Frontiers in Pharmacology|July 23, 2026
Camrelizumab plus CAPOX versus CAPOX for HER2-negative gastric or gastro-oesophageal junction adenocarcinoma: a cost-effectiveness analysisLing Fang, Longfeng Zhang, Lisheng Huang, et al.Cancer Management and Research|November 22, 2019
Cost-Effectiveness Analysis Of Ceritinib And Alectinib Versus Crizotinib In The Treatment Of Anaplastic Lymphoma Kinase-Positive Advanced Non-Small Cell Lung CancerMaobai Liu, Longfeng Zhang, Qishu Huang, et al.Cancer Management and Research|June 7, 2021
Cost-Effectiveness Analysis of Dacomitinib versus Gefitinib in the First-Line Treatment of EGFR-Positive Advanced or Metastatic Non-Small Cell Lung CancerLongfeng Zhang, Na Li, Maobai Liu, et al.Pageof 5